Volume 42 (2024) – Supplementary Issue 1 – Article 15 – Epitheorese Klinikes Farmakologias kai Farmakokinetikes
Background: One effective second-generation triptan for migraine attacks is sumatriptan. Following oral use, it has a 40% restricted bioavailability because of the first-pass metabolism. Aim: To develop the best intranasal Solusomes formula as a substitute that delivers into the brain directly, improving its bioavailability, and removing the first-pass outcome was the aim of this effort. Continue reading